PYC Therapeutics Ltd (FRA:PH7)
€ 0.089 0 (0%) Market Cap: 308.41 Mil Enterprise Value: 268.31 Mil PE Ratio: 0 PB Ratio: 11.56 GF Score: 33/100

PYC Therapeutics Ltd at ICR Virtual Conference Transcript

Jan 14, 2021 / 01:30PM GMT
Release Date Price: €0.095 (+3.83%)
Chris Brinzey
Westwicke ICR - Moderator

Good morning, everyone, and welcome to day four of the 2021 Virtual ICR Conference. My name is Chris Brinzey, and I'm a member of the Westwicke ICR life sciences team. And it's my pleasure to introduce our next presenting company, PYC Therapeutics.

To take you through the story this morning, we have Sahm Nasseri, the Chief Executive Officer of US Operations.

A quick programming note before turning it over to Sahm, I just want to remind everyone who's on the webcast. (Conference Instructions) And with that, I'll pass it to you, Sahm.

Sahm Nasseri
PYC Therapeutics Ltd - CEO of US Operations

Thanks, Chris, and hi, everybody. Thanks for joining this session on PYC Therapeutics. My name is Sahm Nasseri and I am the CEO of PYC in the US. We are a biotechnology company at the moment that is heavily based in Australia, but we are building quite broadly in the US to support multiple of our drug programs moving into clinical development.

Before I tell you a little bit more about our story, I just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot